Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D., to its Board of Directors. Read More.

Fulcrum Therapeutics Appoints Renowned Experts in CNS Disorders and Muscular Dystrophies to Serve on Newly Formed Scientific Advisory Board

 

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control, today announced that it has formed a Scientific Advisory Board (SAB) comprised of renowned experts in the biology of central nervous system (CNS) disorders and muscular dystrophies to help guide the development of the company’s emerging therapeutic programs. Read More.

FierceBiotech names Fulcrum Therapeutics as one of its “Fierce 15” Biotech Companies of 2016

 

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control, announced that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.  

Third Rock Ventures Launches Fulcrum Therapeutics with $55 Million Series A Investment

 

Third Rock Ventures, LLC today announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will discover and develop small molecules that modulate the on/off control mechanisms that regulate genes.